Pancreatic Cancer Research

Journal articleInt J Nanomedicine2014

MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer.

Journal
Int J Nanomedicine
Published
3 July 2014
Citations
37
Type
Article
License
cc by-nc

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

abstract cc by-nc

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and mortal cancer, characterized by a set of known mutations, invasive features, and aberrant microRNA expression that have been associated with hallmark malignant properties of PDAC. The lack of effective PDAC treatment options prompted us to investigate whether microRNAs would constitute promising therapeutic targets toward the generation of a gene therapy approach with clinical significance for this disease. … Excerpt only: this text is the publisher’s. Read it in full at the source.